Pfizer Flexes Muscle With Priciest Purchase of Decade

... the transaction starts to look cheaper -- more like 10 times Ebitda, said Kevin Kedra, an analyst for Gabelli & Co. in Rye, New York. "It's certainly a high price, but Pfizer is paying a premium for the biosimilar assets which are still a small ...

http://ift.tt/1xreUN3